Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 9201199.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemotherapy has been shown to prolong survival and to be cost effective in the palliative treatment of non-small-cell lung cancer. A meta-analysis of 11 randomised trials has found a small benefit from combination chemotherapy in advanced NSCLC, increasing one-year survival rates from 5% to 15%. New combination regimens, especially carboplatin-paclitaxel, show higher response rates in selected patients, and promise improved survival rates, but this has yet to be confirmed in randomised trials.